The CD4+/CD14+HLA-DRlo/neg Ratio as a Prognostic Biomarker in Cancer Patients

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-1-s1-p50
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Identification of F5 as a Prognostic Biomarker in Patients With Gastric Cancer

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2020English

Disseminated Tumour Cells as a Prognostic Biomarker in Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2011English

Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker

Cancers
Cancer ResearchOncology
2019English

Reply to Neutrophil-To-Lymphocyte Ratio as a Bladder Cancer Biomarker: Assessing Prognostic and Predictive Value in SWOG 8710

Cancer
Cancer ResearchOncology
2017English

Identification of a Three miRNA Signature as a Novel Potential Prognostic Biomarker in Patients With Blaader Cancer

Oncotarget
Oncology
2017English

MicroRNA-Gene Association as a Prognostic Biomarker in Cancer Exposes Disease Mechanisms

PLoS Computational Biology
Molecular NeuroscienceEvolutionEcologyGeneticsBehaviorMolecular BiologySystematicsSimulationCellularComputational TheoryMathematicsModeling
2013English

Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer

Journal of Cancer
Oncology
2017English

Prognostic Value of Aspartate Aminotransferase to Platelet Ratio Index as a Noninvasive Biomarker in Patients With Hepatocellular Carcinoma: A Meta-Analysis

Cancer Management and Research
Oncology
2018English

Analysis of Interleukin-13 Receptor Alpha2 Expression as a Prognostic Biomarker in Surgically Resected Pancreatic Cancer Patients

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy